RS BioTherapeutics

Executive Summary

RS BioTherapeutics is a US-based private biotech company founded in 2018 and headquartered in Cumberland, Maryland. The company is dedicated to developing novel therapeutics for diseases characterized by pulmonary inflammation, with a mission to provide life-changing alternatives to corticosteroids. Its lead program, RSBT-001, is a first-in-class therapy derived from anti-inflammatory cannabinoids that targets multiple pathways in the lung's inflammatory cascade. RSBT-001 aims to address respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD), where current treatments often have side effects or limited efficacy. By leveraging the anti-inflammatory properties of cannabinoids, RSBT-001 could offer a new mechanism of action for patients with unmet medical needs. The company operates in the respiratory, infectious disease, and dermatology categories, indicating potential expansion into other inflammatory indications. RS BioTherapeutics is in an early stage, with no disclosed funding or pipeline details beyond RSBT-001. The company's unique approach to pulmonary inflammation positions it as a potential disruptor in the respiratory therapeutic space, though significant development and regulatory hurdles remain. The lack of public information on its clinical stage or financing suggests it may still be in preclinical or early clinical phases. Success will depend on advancing RSBT-001 through clinical trials, securing funding, and demonstrating safety and efficacy. Given the novelty of cannabinoid-based therapies and the competitive landscape, RS BioTherapeutics faces both opportunities and challenges in bringing its candidate to market.

Upcoming Catalysts (preview)

• Q2 2027IND Filing for RSBT-00160% success
• Q4 2026Series A Funding Round50% success
• Q1 2027Preclinical Proof-of-Concept Data Release70% success